Hunan Nucien Pharmaceutical Co. Ltd. Class ASSE: 688189

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint

· Issued by Hunan Nucien Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment